The MUCOR‑ADVANCE Program brings together world‑leading investigators who have collaborated for more than two decades to transform our understanding of mucormycosis. Through pioneering work, this team has defined key mechanisms of mucormycosis pathogenesis, uncovered host immune responses, advanced innovative diagnostics, and identified promising immunomodulatory adjunctive therapies.

​

​

Despite major progress, mucormycosis research has remained largely siloed—limited by fragmented data integration and an overreliance on retrospective human samples. MUCOR‑ADVANCE was created to overcome these barriers. By integrating complementary research supported by three specialized cores, the program is designed to comprehensively elucidate the immunopathogenesis of mucormycosis and advance risk stratification, diagnosis, and clinical management.

​​

​

Our approach emphasizes synergy, collaboration, and translation. By integrating prospectively collected patient specimens with deeply annotated clinical data, MUCOR‑ADVANCE maximizes real‑world relevance and accelerates discovery from bench to bedside. Through the coordinated, multidisciplinary framework, these ambitious and urgently needed advances can be achieved.